Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2005
10/04/2005CA2301706C Use of phanquinone for the treatment of alzheimer's disease
10/04/2005CA2245539C Condensed 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
09/2005
09/29/2005WO2005090388A1 Alpha helical mimics, their uses and methods for their production
09/29/2005WO2005090340A1 Piperidine-1-carboxamide derivative
09/29/2005WO2005090332A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005WO2005090330A1 N-piperidine derivates as ccr3 modulators
09/29/2005WO2005090285A1 Novel crystal of triterpene derivative
09/29/2005WO2005089802A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
09/29/2005WO2005089800A1 PHARMACEUTICAL COMPOSITION CONTAINING hsHRD3
09/29/2005WO2005089781A1 Method of preventing nodavirus infection and therapeutic method
09/29/2005WO2005089776A1 Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
09/29/2005WO2005089745A1 Salvinorin derivatives and uses thereof
09/29/2005WO2005089714A1 Emulsion stabilizer
09/29/2005WO2004072037A8 2,3'-bipyridines derivatives as selective cox-2 inhibitors
09/29/2005US20050215786 Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,,2,4-triazol-3-one
09/29/2005US20050215620 Method of treating amyloid beta precursor disorders
09/29/2005US20050215613 with indazole or thienopyrazole compounds such as 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl-indazole
09/29/2005US20050215602 E. g., 2',3',4',5,5',6,7,8,9,10-decahydro-2-(2-pyrid-3-yl-ethanediylidene-),5'-(2,2,2-trifluoroethyl)-spiro(6,9-methanobenzocyclooctene-11,3'-1,2,5-thiadiazole-1',1'-dioxide; inhibitors of gamma-secretase to modulate the processing of amyloid precursor protein (APP)
09/29/2005US20050215584 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
09/29/2005US20050215569 Inhibiting sodium ion flux through voltage dependent sodium channelswith pyrazopyrimidines for treatment of nervous system disorders, and for treatment of pain or inflammation
09/29/2005US20050215565 Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents
09/29/2005US20050215563 Proteomimetic compounds and methods
09/29/2005US20050215560 5-{2-[4-[1-(4-fluoro-2-hydroxy-phenyl)-methanoyl]-piperidine-1-yl]-(ethyl or propyl)amino}-(optional 2-alkyl)-2H-pyridazine-3-one; hydrogenation of the isoxazolyl-alkylamino-pyridazinone; anxiolytic agents
09/29/2005US20050215559 2-substituted, especially 2-amino-substituted, e.g., [N-(1-ethyl)propyl]-5-(2,4-dimethoxyphenyl)-3,6-dimethylpyrazine-2-amine; bind with high affinity and high selectivity to CRF1 receptors and are used to treat central nervous system disorders
09/29/2005US20050215555 Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma
09/29/2005US20050215553 For therapy and prophylaxis of cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers
09/29/2005US20050215550 Pyrazole-derived kinase inhibitors and uses thereof
09/29/2005US20050215549 TACE inhibitors
09/29/2005US20050215541 Alzheimer's disease; benzodiazapines
09/29/2005US20050215528 Gnrh agonist combination drugs
09/29/2005US20050215520 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
09/29/2005US20050215502 Regulation of endogenous gene expression in cells using zinc finger proteins
09/29/2005US20050215497 Treating prostate cancer by administering double stranded oligonucleotide having two complementary oligonucleotide sequences forming a hybrid; each sequence has at one 3' or 5' end 1-5 unpaired nucleotides forming single-strand ends extending beyond the hybrid
09/29/2005US20050215483 Peptide inhibitors of protein kinase c
09/29/2005US20050215480 Alpha conotoxin peptides with analgesic properties
09/29/2005US20050215477 Treating agonist disorderssuch asd diabetes, obesity, heart dysfunctions, AIDS-related wasting, and kidney, neurological, whole body growth disorders by administering a crystal of an insulin-like growth factor-1 that diffracts x-ray radiation to produce a three-dimensional diffraction pattern
09/29/2005US20050214903 O-superfamily conotoxin peptides
09/29/2005US20050214888 Using animal models to isentify modulators of cAMP responsive element binding protein (CREB) activity; for treatment and prevention of brain and cell proliferative disorders; antisense agents; antitumor agents
09/29/2005US20050214837 Antibody specific for mutant presenilin 1 and method of use thereof
09/29/2005US20050214813 Amyloid-beta protein aggregation-regulating factors
09/29/2005US20050214392 Treatments for immune systems disorders
09/29/2005US20050214391 Method and composition for the treatment of dermatologic diseases
09/29/2005US20050214384 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
09/29/2005US20050214353 Matrix for administering ergoline compounds such as lisuride; restless leg syndrome; circadian rhythm disorders; Parkinson's disease
09/29/2005US20050214334 Composition for topical substance delivery
09/29/2005US20050214293 Containing heavy and light chain complementarity determining region 1,2 and 3 components of amino acid sequences 1-6; reduced immunogenicity; increased affinity and avidity; improved cell culturing
09/29/2005US20050214291 Treatment method
09/29/2005US20050214281 G-protein coupled receptor
09/29/2005DE102004012068A1 Neue alkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel New alkyl-containing 5-Acylindolinone, their preparation and their use as medicaments
09/29/2005DE102004012045A1 Solid pharmaceutical composition containing tropane type inhibitor of neurotransmitter reuptake, useful for treating central nervous system disorders
09/29/2005CA2562388A1 Emulsion-stabilized preparation
09/29/2005CA2560953A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
09/29/2005CA2560767A1 Novel crystal of triterpene derivative
09/29/2005CA2560300A1 Method of preventing nodavirus infection and therapeutic method
09/29/2005CA2560286A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005CA2559665A1 Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
09/29/2005CA2559221A1 Methods for the treatment of synucleinopathies
09/29/2005CA2559211A1 Detection, isolation and uses of renalase (monoamine oxidase c)
09/29/2005CA2559207A1 Salvinorin derivatives and uses thereof
09/29/2005CA2559196A1 Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivates, their manufacture and use as pharmaceutical agents
09/29/2005CA2559105A1 Benzisoxazoles
09/29/2005CA2559047A1 N-substituted benzene sulfonamides
09/29/2005CA2558126A1 The treatment of inflammatory disorders and pain using beta-aminoalcohols
09/29/2005CA2558058A1 N-piperidine derivates as ccr3 modulators
09/29/2005CA2558030A1 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
09/29/2005CA2558020A1 Use of renin inhibitors in therapy
09/29/2005CA2554855A1 Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
09/28/2005EP1580192A2 16-Hydroxyestratrienes as selective estrogens
09/28/2005EP1580188A1 Aryl ureas as kinase inhibitors
09/28/2005EP1579868A2 Use of IL-11 for treating various diseases
09/28/2005EP1579858A1 Novel use of peptide compounds for treating pain in painful diabetic neuropathy
09/28/2005EP1578988A2 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
09/28/2005EP1578917A2 Multimeric proteins and methods of making and using same
09/28/2005EP1578915A2 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
09/28/2005EP1578914A2 Human ion channels
09/28/2005EP1578912A2 Il-13 mutein proteins, antibodies, compositions, methods and uses
09/28/2005EP1578902A2 Neurotransmission-associated proteins
09/28/2005EP1578899A2 Secreted proteins
09/28/2005EP1578797A1 The transmembrane protein amigo and uses thereof
09/28/2005EP1578787A1 Novel chi-conotoxin peptides (-ii)
09/28/2005EP1578746A1 Oxazoles as mglur1 enhancer
09/28/2005EP1578740A1 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
09/28/2005EP1578738A1 Escitalopram hydrobromide and a method for the preparation thereof
09/28/2005EP1578728A1 5-aminophenanthridine derivatives as npy-5 antagonists
09/28/2005EP1578428A2 Treating alcohol and or substance abuse by antagonizing alpha a2 drenergic receptors with weak dopamine blocking
09/28/2005EP1578425A1 Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
09/28/2005EP1578420A2 Treatment of cognitive impairment using a selective dopamine d1 receptor agonist
09/28/2005EP1578416A1 Medicaments containing substituted 2,5-diaminomethyl-1h-pyrroles
09/28/2005EP1578412A2 Pharmaceutical compositions and method of treating parkinson's disease
09/28/2005EP1578409A1 Uses of adenosine a2a receptor antagonists
09/28/2005EP1578253A2 Prevention and treatment of synucleinopathic disease
09/28/2005EP1463731B1 Dibenzodiazepine derivates, their preparation and use
09/28/2005EP1373258B1 Ether derivatives useful as inhibitors of pde4 isozymes
09/28/2005EP1366029B1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents
09/28/2005EP1361880B1 6-substituted pyrido-pyrimidines
09/28/2005EP1318815B1 Use of the combination of nicotinic acid or derivatives with riboflavin in the manufacture of a medicament for the treatment of primary headaches
09/28/2005EP1307430B1 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
09/28/2005EP1299365B1 2-aminothiazoline derivatives and their use as no-synthase inhibitors
09/28/2005EP1299103B1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
09/28/2005EP1296722B1 Radiotherapy
1 ... 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 ... 1833